Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.
Nuchev Limited reported a robust 30% increase in group revenue to $6.5 million in Q1 FY26, driven by strong sales across ANZ, China, and a new foothold in Vietnam. The company’s strategic acquisitions and product launches underpin its expanding market presence and diversification.
Nuchev Limited reported a remarkable FY25 with revenue doubling to $22.9 million, driven by strong growth in Oli6® Nutritional sales and the acquisition of bWellness. The company improved margins, reduced losses, and expanded into new international markets including Vietnam.
Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.
Nuchev Limited reported a remarkable 215% increase in quarterly revenue, driven by the strategic launch of Oli6® in Vietnam and the acquisition of bWellness, signaling robust expansion across key Asia-Pacific markets.